FDA approves use of Evusheld

FDA approves use of Evusheld

The Food and Drug Administration has approved the use of Evusheld, a combination of long-acting antibodies, for prevention of Covid-19, FDA director Paisal Dankhum said on Wednesday.

Evusheld combines monoclonal antibodies for the prevention, not treatment, of Covid-19. It is not intended to be a substitute for coronavirus vaccines.

It was developed by AstraZeneca and approved by the FDA for emergency use on June 27. It has also been authorised for emergency use by the US Food and Drug Administration and the European Union.

Evusheld is a combination of two active substances, tixagevimab co-packaged with cilgavimab, and works on the principle of "passive immunisation".

It is administered as two injections, with protection lasting for at least six months.

It can be used in adults and children from 12 years of age up weighing at least 40 kilogrammes.

Dr Paisal said people who need to use this medicine should provide doctors with information such as their history of allergies, treatment for coronary artery disease, pregnancy and vaccination history.

Do you like the content of this article?
COMMENT (6)

Rights commission expresses concern about hunger strike

The National Human Rights Commission (NHRC) has expressed concern about a hunger strike by two young political activists and called on all sides to urgently find a resolution to prevent possible losses.

28 Jan 2023

US police beating video stirs outrage

MEMPHIS, Tennessee: About 50 protesters gathered Friday night in Memphis demanding justice after a video was released showing police violently arresting Tyre Nichols, a young Black man who died a few days after the incident.

28 Jan 2023

Sabalenka triumphs in Melbourne

MELBOURNE: An emotional Aryna Sabalenka battled back from a set down to beat Elena Rybakina and win the Australian Open on Saturday for her first Grand Slam title.

28 Jan 2023